Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5fe2o3.9h2o
2. Ferric Hydroxide Oxide
3. Ferric Hydroxide Oxide (feooh)
4. Ferric Oxy-hydroxide
5. Ferric Oxyhydroxide (feo2h)
6. Ferrihydrite
7. Iron Hydroxide Oxide (fe(oh)o)
8. Iron Hydroxide Oxide (feo(oh))
9. Iron(iii) Oxyhydroxide
1. Iron Hydroxide Oxide
2. Iron(3+);oxygen(2-);hydroxide
3. Iron Hydroxide Oxide Nanoparticles / Nanopowder
4. Iron Oxide Hydroxide
5. Iron Hydroxide Nanorods
6. Ferric Oxy-hydroxide
7. Ferric Hydroxide [mi]
8. Dtxsid3042057
9. Ferric Oxyhydroxide (feo2h)
10. Ferric Hydroxide Oxide (feooh)
11. Db14695
12. Iron Hydroxide Oxide (feo(oh))
13. Iron Oxide Hydroxide, Aqueous Nanoparticle Dispersion, <5 Nm (dls), 20% Solids By Weight, Ph ~3, 99.5% Trace Metals Basis
1. Feojectin
2. Ferplex Ss
3. Ferrivenin
4. Iviron
5. Proferrin
6. Sucrofer
7. Iron Sugar
8. Saccharated Iron
9. Venoferrum
10. Fesin
11. Ferrum Vitis
12. Hippiron
13. Ferum Hausmann
Molecular Weight | 88.85 g/mol |
---|---|
Molecular Formula | FeHO2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 88.932590 g/mol |
Monoisotopic Mass | 88.932590 g/mol |
Topological Polar Surface Area | 2 Ų |
Heavy Atom Count | 3 |
Formal Charge | 0 |
Complexity | 0 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Velphoro |
PubMed Health | Sucroferric Oxyhydroxide (By mouth) |
Drug Classes | Phosphate Binder |
Active Ingredient | Sucroferric oxyhydroxide |
Dosage Form | Tablet, chewable |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vifor Fresenius |
2 of 2 | |
---|---|
Drug Name | Velphoro |
PubMed Health | Sucroferric Oxyhydroxide (By mouth) |
Drug Classes | Phosphate Binder |
Active Ingredient | Sucroferric oxyhydroxide |
Dosage Form | Tablet, chewable |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vifor Fresenius |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-04
Pay. Date : 2016-07-14
DMF Number : 28865
Submission : 2016-07-07
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-11-30
Written Confirmation Number : WC-0390
Address of the Firm :
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33643
Submission : 2019-03-30
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34957
Submission : 2020-06-30
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-10
Pay. Date : 2023-09-28
DMF Number : 38610
Submission : 2023-07-31
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-04-26
Pay. Date : 2019-02-19
DMF Number : 33020
Submission : 2018-08-09
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-08-04
Pay. Date : 2014-05-22
DMF Number : 27258
Submission : 2013-07-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31315
Submission : 2017-01-03
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Announces Publication Of Results from Phase 2 Study Evaluating RBT-1
Details : RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2024
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surg...
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2023
Details:
The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Juniper Point
Deal Size: $72.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 12, 2023
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Juniper Point
Deal Size : $72.0 million
Deal Type : Series B Financing
Details : The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iro...
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 12, 2023
Details:
The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery.
Lead Product(s): Stannic Protoporfin,Iron Sucrose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 18, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $47.0 million
Deal Type : Series B Financing
Details : The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surg...
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 18, 2023
Details:
RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2023
Details:
RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial
Details : RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2023
Details:
Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.
Lead Product(s): Iron Sucrose
Therapeutic Area: Nephrology Brand Name: Velphoro
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
VFMCRP Announces U.S. Court Upholds Validity of Velphoro® Patent
Details : Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.
Brand Name : Velphoro
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2022
Details:
RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial
Details : RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2022
Details:
Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a cardiac surgery setting.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Nephrology Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 15, 2022
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $35.0 million
Deal Type : Series A Financing
Details : Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a ...
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 15, 2022
Details:
This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Lead Product(s): Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: RBT-1
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
Details : This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.
Brand Name : RBT-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 11, 2021
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?